BRPI0406552A - Uso de l-carnitina para o tratamento de doenças cardiovasculares - Google Patents

Uso de l-carnitina para o tratamento de doenças cardiovasculares

Info

Publication number
BRPI0406552A
BRPI0406552A BR0406552-2A BRPI0406552A BRPI0406552A BR PI0406552 A BRPI0406552 A BR PI0406552A BR PI0406552 A BRPI0406552 A BR PI0406552A BR PI0406552 A BRPI0406552 A BR PI0406552A
Authority
BR
Brazil
Prior art keywords
carnitine
treatment
per day
myocardial infarction
grams per
Prior art date
Application number
BR0406552-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Aleardo Koverech
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of BRPI0406552A publication Critical patent/BRPI0406552A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR0406552-2A 2003-04-17 2004-03-03 Uso de l-carnitina para o tratamento de doenças cardiovasculares BRPI0406552A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000178A ITRM20030178A1 (it) 2003-04-17 2003-04-17 Uso della l-carnitina per il trattamento di patologie cardiovascolari.
PCT/IT2004/000107 WO2004091602A1 (en) 2003-04-17 2004-03-03 Use of l-carnitine for the treatment of cardiovascular diseases

Publications (1)

Publication Number Publication Date
BRPI0406552A true BRPI0406552A (pt) 2005-12-20

Family

ID=29765768

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0406552-2A BRPI0406552A (pt) 2003-04-17 2004-03-03 Uso de l-carnitina para o tratamento de doenças cardiovasculares

Country Status (11)

Country Link
US (1) US20060052450A1 (enExample)
EP (1) EP1613301A1 (enExample)
JP (1) JP2006523685A (enExample)
KR (1) KR20050121196A (enExample)
CN (2) CN101467992A (enExample)
AU (2) AU2004229256A1 (enExample)
BR (1) BRPI0406552A (enExample)
CA (1) CA2508636A1 (enExample)
IT (1) ITRM20030178A1 (enExample)
MX (1) MXPA05007612A (enExample)
WO (1) WO2004091602A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20040346A1 (it) * 2004-07-13 2004-10-13 Sigma Tau Ind Farmaceuti Uso della l-carnitina per il trattamento di patologie cardiovascolari.
US20070260674A1 (en) * 2006-05-02 2007-11-08 Research In Motion Limited Push framework for delivery of dynamic mobile content
EP2268304A2 (en) * 2008-03-26 2011-01-05 Orthologic Corp. Methods for treating acute myocardial infarction
EP2353596A1 (en) 2010-02-02 2011-08-10 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Combination composition, comprising as active ingredients L-carnitine or propionyl L-carnitine, for the prevention or treatment of chronic venous insufficiency
WO2012150146A1 (en) 2011-05-03 2012-11-08 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Composition useful for the treatment of lipid metabolism disorders
CN114073705A (zh) * 2020-08-14 2022-02-22 常州高新技术产业开发区三维工业技术研究所有限公司 一种降尿酸药物组合物及其应用
CN112180013B (zh) * 2020-09-29 2022-11-15 上海脉示生物技术有限公司 用于心肌梗死诊断的肠道微生物代谢标志物组合物及其检测方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS531812B2 (enExample) * 1972-12-07 1978-01-23
WO2000030637A1 (en) * 1998-11-26 2000-06-02 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of fumarate salt of l-carnitine or its alkanoyl derivatives in ischaemia

Also Published As

Publication number Publication date
CA2508636A1 (en) 2004-10-28
EP1613301A1 (en) 2006-01-11
ITRM20030178A0 (it) 2003-04-17
AU2010202396A1 (en) 2010-07-01
KR20050121196A (ko) 2005-12-26
ITRM20030178A1 (it) 2004-10-18
MXPA05007612A (es) 2005-09-30
US20060052450A1 (en) 2006-03-09
AU2004229256A1 (en) 2004-10-28
CN1717232A (zh) 2006-01-04
WO2004091602A1 (en) 2004-10-28
JP2006523685A (ja) 2006-10-19
CN101467992A (zh) 2009-07-01

Similar Documents

Publication Publication Date Title
Angulo et al. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid
CU23468B7 (es) Forma de dosificación de pramipexol en una dosis única diaria
KR102376794B1 (ko) 담즙정체성 소양증의 치료
UA102517C2 (ru) Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы
BR112014027010A2 (pt) uso de laquinimod de alta dose para tratamento de esclerose múltipla
EP1369119B1 (en) Il-12 expression controlling agents
BR0008969A (pt) Cloreto den-[2-hidróxi-3-(1-piperidinil)-(propóxi]piridina-1-óxido-3-carboximidoìla e seu uso no tratamento deresistência à insulina
BRPI0406552A (pt) Uso de l-carnitina para o tratamento de doenças cardiovasculares
CA2302568A1 (en) Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
PE20241327A1 (es) Tratamiento de trastornos hepaticos con un agonista del thr-beta
MXPA02012730A (es) Uso de acido pamoico o uno de sus derivados o uno de sus analogos para la preparacion de un medicamento para el tratamiento de enfermedades caracterizadas por depositos de agregados de amiloide.
BR0013252A (pt) Micofenolato mofetila em associação com peg-ifn-alfa
BR0316131A (pt) Acetil-l-carnitina para a prevenção e/ou tratamento de neuropatias periféricas induzidas por agentes anti-câncer
BR0308038A (pt) Ambroxol para o tratamento de estados doloridos na cavidade bucal e faringe
ES2343166T3 (es) Activadores para el receptor activado por proliferador de peroxisoma.
BR0308045A (pt) Aplicação de 3-fenil-5-alcóxi-1,3,4-oxdiazol-2-onas substituìdas para a preparação de medicamentos com efeito inibidor na lipase pancreática
AR029666A1 (es) Uso del (+) -alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinmetanol o su prodroga para la manufactura de un medicamento en el tratamiento de los sintomas de la demencia y de la psicosis inducida por dopamina
IE851848L (en) Propiophenone compound against sexual dysfunction
PT786998E (pt) A utilizacao de ¬r-(z)|-alfa-(metoxiimino)-alfa-(1-azabiciclo-¬2.2.2|-oct-3-il) acetonitrilo para reduzir a formacao de beta amiloide a4 na doenca de alzheimer
WO2009088939A2 (en) Compositions and methods for treating neurodegenerative diseases
KR20080028389A (ko) 양극성 장애를 치료하기 위한 약제의 수득에 있어서의아고멜라틴의 용도
BRPI0413750A (pt) uso de loxapina ou de um seu sal farmaceuticamente aceitável, composição farmacêutica, e, kit
BRPI0513303A8 (pt) Uso de l-carnitina para o tratamento de doenças cardiovasculares
CY1114250T1 (el) Ακετυλ l-καρνιτινη για την προληψη της επιπονης περιφερικης διαβητικης νευροπαθειας
PT1769798E (pt) Nova associação entre a agomelatina e um inibidor da recaptação da noradrenalina e as composições farmacêuticas que a contenham

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 9A E 10A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2257 DE 08/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A E 16A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.